Amanda Peppercorn

1.9k total citations
39 papers, 1.1k citations indexed

About

Amanda Peppercorn is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Amanda Peppercorn has authored 39 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Infectious Diseases, 17 papers in Epidemiology and 6 papers in Virology. Recurrent topics in Amanda Peppercorn's work include HIV/AIDS drug development and treatment (16 papers), Influenza Virus Research Studies (6 papers) and HIV Research and Treatment (6 papers). Amanda Peppercorn is often cited by papers focused on HIV/AIDS drug development and treatment (16 papers), Influenza Virus Research Studies (6 papers) and HIV Research and Treatment (6 papers). Amanda Peppercorn collaborates with scholars based in United States, United Kingdom and Japan. Amanda Peppercorn's co-authors include Stephen C. Piscitelli, Julie Borland, Ivy Song, Shuguang Chen, Toshihiro Wajima, Shuguang Chen, Parul Patel, Yu Lou, Paul Savina and Martin Handfield and has published in prestigious journals such as PLoS ONE, PEDIATRICS and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Amanda Peppercorn

35 papers receiving 1.1k citations

Peers

Amanda Peppercorn
Jean‐Luc Meynard France
Christophe Michon France
E.G.L. Wilkins United Kingdom
Henry C. Mwandumba United Kingdom
Ravesh Singh South Africa
Amedeo Capetti Italy
Apostolos Beloukas Greece
J. P. Chave Switzerland
Debbie Marriott Australia
Dante Bassetti Italy
Jean‐Luc Meynard France
Amanda Peppercorn
Citations per year, relative to Amanda Peppercorn Amanda Peppercorn (= 1×) peers Jean‐Luc Meynard

Countries citing papers authored by Amanda Peppercorn

Since Specialization
Citations

This map shows the geographic impact of Amanda Peppercorn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amanda Peppercorn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amanda Peppercorn more than expected).

Fields of papers citing papers by Amanda Peppercorn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amanda Peppercorn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amanda Peppercorn. The network helps show where Amanda Peppercorn may publish in the future.

Co-authorship network of co-authors of Amanda Peppercorn

This figure shows the co-authorship network connecting the top 25 collaborators of Amanda Peppercorn. A scholar is included among the top collaborators of Amanda Peppercorn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amanda Peppercorn. Amanda Peppercorn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Agostini, Maria L., Gretja Schnell, Julia di Iulio, et al.. (2024). Resistance analysis in the phase III COMET-TAIL study: treatment of COVID-19 with intramuscular or intravenous sotrovimab. Future Virology. 19(5). 185–198.
2.
3.
Sager, Jennifer E., Sergio Parra, Jennifer Moore, et al.. (2024). Pharmacokinetics of the Monoclonal Antibody, Sotrovimab, in Healthy Participants Following IM Administration at Different Injection Sites. Clinical Pharmacology & Therapeutics. 117(3). 759–767.
4.
Schnell, Gretja, Julia di Iulio, Anil Kumar Gupta, et al.. (2023). Resistance Analysis Following Sotrovimab Treatment in Participants with COVID-19 During the Phase III COMET-ICE Study. Future Virology. 18(15). 975–990. 2 indexed citations
5.
Sager, Jennifer E., Julie Passarell, Xiaobin Li, et al.. (2023). Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19. CPT Pharmacometrics & Systems Pharmacology. 12(6). 853–864. 5 indexed citations
6.
Mehta, Nalini, et al.. (2023). Lessons from resistance analysis in clinical trials of IV zanamivir. Virus Research. 325. 199039–199039.
7.
Wang‐Jairaj, Jie, et al.. (2021). Zanamivir aqueous solution in severe influenza: A global Compassionate Use Program, 2009–2019. Influenza and Other Respiratory Viruses. 16(3). 542–551. 12 indexed citations
8.
Johnson, Mark, Roxanne C. Jewell, Amanda Peppercorn, et al.. (2018). The safety, tolerability, and pharmacokinetic profile of GSK2838232, a novel 2nd generation HIV maturation inhibitor, as assessed in healthy subjects. Pharmacology Research & Perspectives. 6(4). e00408–e00408. 16 indexed citations
9.
Marty, Francisco M., Carol L. Clark, Sandeep K. Gupta, et al.. (2017). Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. The Lancet Respiratory Medicine. 5(2). 135–146. 83 indexed citations
10.
Bradley, John S., Jeffrey L. Blumer, José R. Romero, et al.. (2017). Intravenous Zanamivir in Hospitalized Patients With Influenza. PEDIATRICS. 140(5). 21 indexed citations
11.
12.
Song, Ivy, Julie Borland, Shuguang Chen, et al.. (2014). Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir. European Journal of Clinical Pharmacology. 70(10). 1173–1179. 30 indexed citations
13.
Weller, S, Julie Borland, Shuguang Chen, et al.. (2013). Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment. European Journal of Clinical Pharmacology. 70(1). 29–35. 48 indexed citations
14.
Song, Ivy, Stephen Mark, Shuguang Chen, et al.. (2013). Dolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjects. Drug and Alcohol Dependence. 133(2). 781–784. 15 indexed citations
15.
Dooley, Kelly E., Julie Borland, Shuguang Chen, et al.. (2012). Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin. JAIDS Journal of Acquired Immune Deficiency Syndromes. 62(1). 21–27. 143 indexed citations
16.
Song, Ivy, Julie Borland, Shuguang Chen, et al.. (2011). Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next‐generation HIV integrase inhibitor, S/GSK1349572. British Journal of Clinical Pharmacology. 72(1). 103–108. 55 indexed citations
17.
Peppercorn, Amanda, et al.. (2010). High-Level Human Herpesvirus-6 Viremia Associated With Onset of Stevens-Johnson Syndrome: Report of Two Cases. Journal of Burn Care & Research. 31(2). 365–368. 16 indexed citations
18.
Peppercorn, Amanda, et al.. (2010). Overwhelming Disseminated Herpes Simplex Virus Type 2 Infection in a Patient With Severe Burn Injury: Case Report and Literature Review. Journal of Burn Care & Research. 31(3). 492–498. 10 indexed citations
19.
Weber, David J., et al.. (2009). Preventing healthcare-associatedAspergillusinfections: review of recent CDC/HICPAC recommendations. Medical Mycology. 47(s1). S199–S209. 45 indexed citations
20.
Rollins, Sean M., Amanda Peppercorn, Melissa Drysdale, et al.. (2008). Application of In Vivo Induced Antigen Technology (IVIAT) to Bacillus anthracis. PLoS ONE. 3(3). e1824–e1824. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jean‐Luc Meynard Breakdown of academic impact, for papers by Christophe Michon Breakdown of academic impact, for papers by E.G.L. Wilkins Breakdown of academic impact, for papers by Henry C. Mwandumba Breakdown of academic impact, for papers by Ravesh Singh Breakdown of academic impact, for papers by Amedeo Capetti Breakdown of academic impact, for papers by Apostolos Beloukas Breakdown of academic impact, for papers by J. P. Chave Breakdown of academic impact, for papers by Debbie Marriott Breakdown of academic impact, for papers by Dante Bassetti
Rankless by CCL
2026